Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Jan;69(1):26–30. doi: 10.1136/hrt.69.1.26

Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease.

P Groves 1, A Rees 1, A Bishop 1, R Morgan 1, M Ruttley 1, N Lewis 1, I Lane 1, R Hall 1
PMCID: PMC1024911  PMID: 8457389

Abstract

OBJECTIVE--To investigate the relation between apolipoprotein(a) concentrations and angiographically defined coronary artery disease in patients with atheromatous peripheral vascular disease. DESIGN--40 consecutive patients were recruited at the time of admission for peripheral vascular surgery. All underwent clinical assessment and coronary arteriography. Apolipoprotein(a) concentrations were measured by an immunoradiometric assay. SETTING--Tertiary referral centre. SUBJECTS--Patients requiring surgical intervention for large vessel peripheral vascular disease. MAIN OUTCOME MEASURES--Presence or absence and severity and distribution of angiographically defined coronary artery disease. Measurement of circulating contractions of apolipoprotein(a) and other lipid indices. RESULTS--Coronary artery disease was absent in 11 patients (group 1), mild to moderate in 12 (group 2), and severe in 17 (group 3). The distribution of peripheral vascular disease and of standard lipid indices was similar in these three groups of patients. There was a significant difference in apolipoprotein(a) concentrations between the three groups, with concentrations progressively increasing with the severity of coronary artery disease (mean (95% confidence interval): group 1, 112 U/1 (52 to 242); group 2, 214 U/1 (129 to 355); group 3, 537 U/1 (271 to 1064) (analysis of variance p < 0.005). The prevalence of coronary artery disease was increased 7.4 fold in patients with apolipoprotein(a) concentrations that were greater than the cohort median (206 U/1) (p < 0.01). CONCLUSIONS--The results show an association between apolipoprotein(a) concentrations and angiographically defined coronary artery disease in patients with large vessel peripheral vascular disease. The findings imply differences in the pathogenesis of coronary and peripheral atheroma and suggest that the measurement of apolipoprotein(a) may prove a useful additional tool in the risk factor assessment of patients undergoing peripheral vascular surgery.

Full text

PDF
26

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain C. C., Poon L. S., Chan C. S., Richmond W., Fu P. C. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 Apr;20(4):470–475. [PubMed] [Google Scholar]
  2. Armstrong V. W., Cremer P., Eberle E., Manke A., Schulze F., Wieland H., Kreuzer H., Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986 Dec;62(3):249–257. doi: 10.1016/0021-9150(86)90099-7. [DOI] [PubMed] [Google Scholar]
  3. Bini A., Fenoglio J., Jr, Sobel J., Owen J., Fejgl M., Kaplan K. L. Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood. 1987 Apr;69(4):1038–1045. [PubMed] [Google Scholar]
  4. Boucher C. A., Brewster D. C., Darling R. C., Okada R. D., Strauss H. W., Pohost G. M. Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med. 1985 Feb 14;312(7):389–394. doi: 10.1056/NEJM198502143120701. [DOI] [PubMed] [Google Scholar]
  5. Brandt P. W., Partridge J. B., Wattie W. J. Coronary arteriography; method of presentation of the arteriogram report and a scoring system. Clin Radiol. 1977 Jul;28(4):361–365. doi: 10.1016/s0009-9260(77)80140-2. [DOI] [PubMed] [Google Scholar]
  6. Carlson L. A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989 Oct;226(4):271–276. doi: 10.1111/j.1365-2796.1989.tb01393.x. [DOI] [PubMed] [Google Scholar]
  7. Criqui M. H., Langer R. D., Fronek A., Feigelson H. S., Klauber M. R., McCann T. J., Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 6;326(6):381–386. doi: 10.1056/NEJM199202063260605. [DOI] [PubMed] [Google Scholar]
  8. Durrington P. N., Ishola M., Hunt L., Arrol S., Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988 May 14;1(8594):1070–1073. doi: 10.1016/s0140-6736(88)91895-8. [DOI] [PubMed] [Google Scholar]
  9. Eagle K. A., Coley C. M., Newell J. B., Brewster D. C., Darling R. C., Strauss H. W., Guiney T. E., Boucher C. A. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. Ann Intern Med. 1989 Jun 1;110(11):859–866. doi: 10.7326/0003-4819-110-11-859. [DOI] [PubMed] [Google Scholar]
  10. Eaton D. L., Fless G. M., Kohr W. J., McLean J. W., Xu Q. T., Miller C. G., Lawn R. M., Scanu A. M. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A. 1987 May;84(10):3224–3228. doi: 10.1073/pnas.84.10.3224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fowkes F. G. Aetiology of peripheral atherosclerosis. BMJ. 1989 Feb 18;298(6671):405–406. doi: 10.1136/bmj.298.6671.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  13. Gersh B. J., Rihal C. S., Rooke T. W., Ballard D. J. Evaluation and management of patients with both peripheral vascular and coronary artery disease. J Am Coll Cardiol. 1991 Jul;18(1):203–214. doi: 10.1016/s0735-1097(10)80241-4. [DOI] [PubMed] [Google Scholar]
  14. Gonzalez-Gronow M., Edelberg J. M., Pizzo S. V. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry. 1989 Mar 21;28(6):2374–2377. doi: 10.1021/bi00432a005. [DOI] [PubMed] [Google Scholar]
  15. Gurakar A., Hoeg J. M., Kostner G., Papadopoulos N. M., Brewer H. B., Jr Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985 Nov;57(2-3):293–301. doi: 10.1016/0021-9150(85)90041-3. [DOI] [PubMed] [Google Scholar]
  16. HAUST M. D., WYLLIE J. C., MORE R. H. ATHEROGENESIS AND PLASMA CONSTITUENTS. I. DEMONSTRATION OF FIBRIN IN THE WHITE PLAQUE BY THE FLUORESCENT ANTIBODY TECHNIQUE. Am J Pathol. 1964 Feb;44:255–267. [PMC free article] [PubMed] [Google Scholar]
  17. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  18. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989 May;86(10):3847–3851. doi: 10.1073/pnas.86.10.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hertzer N. R. Basic data concerning associated coronary disease in peripheral vascular patients. Ann Vasc Surg. 1987 Dec;1(5):616–620. doi: 10.1016/S0890-5096(06)61452-0. [DOI] [PubMed] [Google Scholar]
  20. Hertzer N. R., Beven E. G., Young J. R., O'Hara P. J., Ruschhaupt W. F., 3rd, Graor R. A., Dewolfe V. G., Maljovec L. C. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984 Feb;199(2):223–233. doi: 10.1097/00000658-198402000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hughson W. G., Mann J. I., Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. 1978 May 27;1(6124):1379–1381. doi: 10.1136/bmj.1.6124.1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jürgens G., Költringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987 Mar;37(3):513–515. doi: 10.1212/wnl.37.3.513. [DOI] [PubMed] [Google Scholar]
  23. Kostner G. M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G. B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981 Jan-Feb;38(1-2):51–61. doi: 10.1016/0021-9150(81)90103-9. [DOI] [PubMed] [Google Scholar]
  24. Leppo J., Plaja J., Gionet M., Tumolo J., Paraskos J. A., Cutler B. S. Noninvasive evaluation of cardiac risk before elective vascular surgery. J Am Coll Cardiol. 1987 Feb;9(2):269–276. doi: 10.1016/s0735-1097(87)80374-1. [DOI] [PubMed] [Google Scholar]
  25. Loscalzo J., Weinfeld M., Fless G. M., Scanu A. M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990 Mar-Apr;10(2):240–245. doi: 10.1161/01.atv.10.2.240. [DOI] [PubMed] [Google Scholar]
  26. Mangano D. T., Browner W. S., Hollenberg M., London M. J., Tubau J. F., Tateo I. M. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med. 1990 Dec 27;323(26):1781–1788. doi: 10.1056/NEJM199012273232601. [DOI] [PubMed] [Google Scholar]
  27. Marth E., Cazzolato G., Bittolo Bon G., Avogaro P., Kostner G. M. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab. 1982;26(1):56–62. doi: 10.1159/000176544. [DOI] [PubMed] [Google Scholar]
  28. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  29. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  30. Murai A., Miyahara T., Fujimoto N., Matsuda M., Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986 Feb;59(2):199–204. doi: 10.1016/0021-9150(86)90048-1. [DOI] [PubMed] [Google Scholar]
  31. Raby K. E., Goldman L., Creager M. A., Cook E. F., Weisberg M. C., Whittemore A. D., Selwyn A. P. Correlation between preoperative ischemia and major cardiac events after peripheral vascular surgery. N Engl J Med. 1989 Nov 9;321(19):1296–1300. doi: 10.1056/NEJM198911093211904. [DOI] [PubMed] [Google Scholar]
  32. Reid D. D., Holland W. W., Humerfelt S., Rose G. A cardiovascular survey of British postal workers. Lancet. 1966 Mar 19;1(7438):614–618. doi: 10.1016/s0140-6736(66)90820-8. [DOI] [PubMed] [Google Scholar]
  33. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990 Dec 1;301(6763):1248–1251. doi: 10.1136/bmj.301.6763.1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schroll M., Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis. 1981;34(6):261–269. doi: 10.1016/0021-9681(81)90031-x. [DOI] [PubMed] [Google Scholar]
  35. Smith E. B., Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis. 1990 Oct;84(2-3):173–181. doi: 10.1016/0021-9150(90)90088-z. [DOI] [PubMed] [Google Scholar]
  36. Smith E. B., Staples E. M. Haemostatic factors in human aortic intima. Lancet. 1981 May 30;1(8231):1171–1174. doi: 10.1016/s0140-6736(81)92346-1. [DOI] [PubMed] [Google Scholar]
  37. Soma M., Fumagalli R., Paoletti R., Meschia M., Maini M. C., Crosignani P., Ghanem K., Gaubatz J., Morrisett J. D. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet. 1991 Mar 9;337(8741):612–612. doi: 10.1016/0140-6736(91)91674-j. [DOI] [PubMed] [Google Scholar]
  38. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  39. Tomatis L. A., Fierens E. E., Verbrugge G. P. Evaluation of surgical risk in peripheral vascular disease by coronary arteriography: a series of 100 cases. Surgery. 1972 Mar;71(3):429–435. [PubMed] [Google Scholar]
  40. Utermann G., Menzel H. J., Kraft H. G., Duba H. C., Kemmler H. G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987 Aug;80(2):458–465. doi: 10.1172/JCI113093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  42. Warnick G. R., Nguyen T., Albers A. A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem. 1985 Feb;31(2):217–222. [PubMed] [Google Scholar]
  43. Zenker G., Költringer P., Boné G., Niederkorn K., Pfeiffer K., Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986 Sep-Oct;17(5):942–945. doi: 10.1161/01.str.17.5.942. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES